SCHEMBL8209302

SCHEMBL8209302

CC(C)NC(=O)c1cccc(C(=O)NCc2cnn(-c3cncnc3)c2)n1

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ADRB2 P07550 1/20 0.41
KLKB1 P03952 1/20 0.40
KLK1 P06870 1/20 0.40
HPGD P15428 3/20 0.38
ALDH1A1 P00352 3/20 0.38
ROCK2 O75116 2/20 0.38
ROCK1 Q13464 2/20 0.38
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36
POLB P06746 3/20 0.36
RAB9A P51151 1/20 0.36
KDM4E B2RXH2 2/20 0.36
GLS O94925 1/20 0.35
NPSR1 Q6W5P4 2/20 0.35
CNR2 P34972 1/20 0.35
MMP13 P45452 1/20 0.34
HTT P42858 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12853298 0.90 ADRB2 (0.44) ADRB2KLKB1KLK1HPGDALDH1A1
SCHEMBL12853327 0.90 ROCK2 (0.47) ADRB2KLKB1KLK1HPGDALDH1A1
SCHEMBL12853254 0.89 HPGD (0.44) ADRB2KLKB1KLK1HPGDALDH1A1
SCHEMBL8205629 0.88 CNR1 (0.43) ADRB2KLKB1KLK1HPGDALDH1A1
SCHEMBL8213781 0.87 ADRB2 (0.47) ADRB2KLKB1KLK1HPGDALDH1A1
SCHEMBL8206384 0.87 IRAK4 (0.41) ADRB2KLKB1KLK1ROCK2ROCK1
SCHEMBL12853294 0.87 KDM4E (0.44) ADRB2KLKB1KLK1HPGDALDH1A1
SCHEMBL8210996 0.87 DHODH (0.44) ADRB2KLKB1KLK1HPGDKDM4E
SCHEMBL8201431 0.87 KLKB1 (0.50) ADRB2KLKB1KLK1HPGDALDH1A1
SCHEMBL8206372 0.86 ADRB2 (0.42) ADRB2KLKB1KLK1ALDH1A1ROCK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2132178-B1 JNK INHIBITORS MERCK SHARP & DOHME (US) 2015-08-19 EP disclosed
US-8278337-B2 Substituted pyridines that are JNK inhibitors MERCK SHARP & DOHME (US) 2012-10-02 US disclosed
US-8278337-B2 Substituted pyridines that are JNK inhibitors MERCK SHARP & DOHME (US) 2012-10-02 US disclosed
US-20100179141-A1 NOVEL JNK INHIBITORS SCHERING CORPORATION 2010-07-15 US disclosed
US-20100179141-A1 NOVEL JNK INHIBITORS SCHERING CORPORATION 2010-07-15 US disclosed
WO-2008082487-A2 NOVEL JNK INHIBITORS SCHERING CORPORATION (US) 2008-07-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100179141-A1 NOVEL JNK INHIBITORS MAPK1, MAPKAPK5, MAPK15 ADRB2 3238/4885KLKB1 1959/4885KLK1 2703/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.